Ticker Details
Cue Biopharma, Inc. Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
IPO Date:	January 2, 2018
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$65.43M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.26 | 3.96%
Avg Daily Range (30 D):	$0.05 | 13.56%
Avg Daily Range (90 D):	$0.03 | 9.48%

Institutional Daily Volume
Avg Daily Volume:	.48M
Avg Daily Volume (30 D):	14.2M
Avg Daily Volume (90 D):	5.58M

Trade Size
Avg Trade Size (Sh.):	220
Avg Trade Size (Sh.) (30 D):	599
Avg Trade Size (Sh.) (90 D):	586

Institutional Trades
Total Institutional Trades:	183
Avg Institutional Trade:	$2.16M
Avg Institutional Trade (30 D):	$.62M
Avg Institutional Trade (90 D):	$.62M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.18M
Avg Closing Trade (30 D):	$.62M
Avg Closing Trade (90 D):	$.62M
Avg Closing Volume:	8.09K

News

Apr 8, 2026 @ 12:00 PM Cue Biopharma to Receive $7.5 Million Preclinical ... Source: Na

Jul 23, 2025 @ 1:26 PM High‑Growth Oncology Market Projected For U... Source: Prnewswire

Jun 24, 2025 @ 8:48 PM Cue Biopharma Receives FDA Feedback on Pre-IND Bri... Source: N/A

Apr 15, 2025 @ 2:23 AM Cue Biopharma Announces Pricing of Approximately $... Source: Globe Newswire

Apr 15, 2025 @ 2:23 AM Cue Biopharma Announces Pricing of Approximately $... Source: N/A

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.28	$.03	$-.28
Diluted EPS	$-.28	$.03	$-.28
Revenue	$27.47M	$21.94M	$27.47M
Gross Profit
Net Income / Loss	$-26.6M	$1.59M	$-26.6M
Operating Income / Loss	$-26.55M	$1.98M	$-26.55M
Cost of Revenue
Net Cash Flow	$4.68M	$15.44M	$4.68M
PE Ratio

Splits
Apr 24, 2026	1:30